Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News May 18 2026 | BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension Industry News Industry Read More May 12 2026 | New Focus Issue on Inflammatory and Infiltrative Cardiomyopathies in the May Issue of the Journal of Cardiac Failure HFSA News Journal of Cardiac Failure Press Release Read More May 11 2026 | Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure Industry News Industry Read More May 10 2026 | HFSA President's Update: May 2026 HFSA News President's Updates Read More May 6 2026 | BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil Industry News Industry Read More Pagination First page « First Previous page ‹ Previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last »
May 18 2026 | BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension Industry News Industry Read More
May 12 2026 | New Focus Issue on Inflammatory and Infiltrative Cardiomyopathies in the May Issue of the Journal of Cardiac Failure HFSA News Journal of Cardiac Failure Press Release Read More
May 11 2026 | Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure Industry News Industry Read More
May 6 2026 | BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil Industry News Industry Read More
